Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Low-risk MDS and CMML With TET2 Mutations
NCT06630221Phase 2Suspended
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Primary endpoint: Response Rate as assessed by hematologic response at 12 weeks. Started Jun 2025; status: suspended.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06630221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630221.